Evolus (EOLS) Common Equity (2017 - 2026)
Evolus' (EOLS) quarterly Common Equity came in at -$28.8 million in Q1 2026, down 335.81% YoY from $12.2 million in Q1 2025, and down 24.56% on a QoQ basis from -$23.1 million in Q4 2025.
Evolus (EOLS) Common Equity (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Common Equity data on file, last reported at -$28.8 million in Q1 2026.
- Quarterly Common Equity fell 335.81% year-over-year to -$28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.8 million (down 335.81% YoY) and the FY2025 annual result came in at -$23.1 million, down 518.44% from the prior year.
- Common Equity retreated to -$28.8 million in Q1 2026, from -$23.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $67.2 million in Q1 2022 to a low of -$28.8 million in Q1 2026.
- A 5-year average of $3.8 million and a median of $5.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity surged 377.38% — and 2025, when it sank 588.29%.
- Tracing EOLS's Common Equity over 5 years: stood at $18.5 million in 2022, then slumped by 211.84% to -$20.7 million in 2023, then soared by 126.69% to $5.5 million in 2024, then sank by 518.44% to -$23.1 million in 2025, then decreased by 24.56% to -$28.8 million in 2026.
- The last three Common Equity figures came in at -$28.8 million (Q1 2026), -$23.1 million (Q4 2025), and -$28.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.49 Bn | 43.53 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.69 Bn | 40.04 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 32.30 Bn | 30.62 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 21.97 Bn | 19.31 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.97 Bn | 18.08 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.95 Bn | 11.42 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 4.05 Bn |
| 10 | Evolus | 550.84 Mn | 505.67 Mn | 57.18 Mn | -30.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.90 Mn |
| Mar 31, 2026 | -28.78 Mn |
| Dec 31, 2025 | -23.11 Mn |
| Sep 30, 2025 | -28.76 Mn |
| Jun 30, 2025 | -18.65 Mn |
| Mar 31, 2025 | -6.60 Mn |
| Dec 31, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Jun 30, 2024 | 19.31 Mn |
| Mar 31, 2024 | 18.44 Mn |
| Dec 31, 2023 | -20.69 Mn |
| Sep 30, 2023 | -19.37 Mn |
| Jun 30, 2023 | -6.96 Mn |
| Mar 31, 2023 | 6.95 Mn |
| Dec 31, 2022 | 18.50 Mn |
| Sep 30, 2022 | 29.22 Mn |
| Jun 30, 2022 | 46.86 Mn |
| Mar 31, 2022 | 67.25 Mn |
| Dec 31, 2021 | 81.88 Mn |
| Sep 30, 2021 | 97.40 Mn |